Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2013, Article ID 820953, 11 pages
http://dx.doi.org/10.1155/2013/820953
Review Article

Proteomics of Uveal Melanoma: A Minireview

Department of Ophthalmology, Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark

Received 5 May 2013; Accepted 25 June 2013

Academic Editor: Bruno Vincenzi

Copyright © 2013 Søren K. O. Abildgaard and Henrik Vorum. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Singh and A. Topham, “Incidence of uveal melanoma in the United States: 1973–1997,” Ophthalmology, vol. 110, no. 5, pp. 956–961, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. D. Singh and A. Topham, “Survival rates with uveal melanoma in the United States: 1973–1997,” Ophthalmology, vol. 110, no. 5, pp. 962–965, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Bergman, B. Nilsson, G. Lundell, M. Lundell, and S. Seregard, “Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population,” Ophthalmology, vol. 112, no. 5, pp. 834–840, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. D. Singh, I. G. Rennie, T. Kivela, S. Seregard, and H. Grossniklaus, “The Zimmerman-McLean-Foster hypothesis: 25 years later,” British Journal of Ophthalmology, vol. 88, no. 7, pp. 962–967, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Augsburger and J. W. Gamel, “Clinical prognostic factors in patients with posterior uveal malignant melanoma,” Cancer, vol. 66, no. 7, pp. 1596–1600, 1990. View at Google Scholar · View at Scopus
  6. L. Kodjikian, J.-D. Grange, S. Baldo, S. Baillif, J. G. Garweg, and M. Rivoire, “Prognostic factors of liver metastases from uveal melanoma,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 10, pp. 985–993, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. E. Margo, “The collaborative ocular melanoma study: an overview,” Cancer Control, vol. 11, no. 5, pp. 304–309, 2004. View at Google Scholar · View at Scopus
  8. E. Kujala, T. Mäkitie, and T. Kivelä, “Very long-term prognosis of patients with malignant uveal melanoma,” Investigative Ophthalmology & Visual Science, vol. 44, no. 11, pp. 4651–4659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Arnesen and M. Nornes, “Malignant melanoma of the choroid as related to coexistent benign nevus,” Acta Ophthalmologica, vol. 53, no. 2, pp. 139–152, 1975. View at Google Scholar · View at Scopus
  10. C. L. Shields, M. Furuta, E. L. Berman et al., “Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases,” Archives of Ophthalmology, vol. 127, no. 8, pp. 981–987, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Shields, C. L. Shields, P. de Potter, and A. D. Singh, “Diagnosis and treatment of uveal melanoma,” Seminars in Oncology, vol. 23, no. 6, pp. 763–767, 1996. View at Google Scholar · View at Scopus
  12. S. Frenkel, I. Nir, K. Hendler et al., “Long-term survival of uveal melanoma patients after surgery for liver metastases,” British Journal of Ophthalmology, vol. 93, no. 8, pp. 1042–1046, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Eskelin, S. Pyrhönen, P. Summanen, J. U. Prause, and T. Kivelä, “Screening for metastatic malignant melanoma of the uvea revisited,” Cancer, vol. 85, pp. 1151–1159, 1999. View at Publisher · View at Google Scholar
  14. I. Kaiserman, R. Amer, and J. Pe'er, “Liver function tests in metastatic uveal melanoma,” American Journal of Ophthalmology, vol. 137, no. 2, pp. 236–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Pach and D. M. Robertson, “Metastasis from untreated uveal melanomas,” Archives of Ophthalmology, vol. 104, no. 11, pp. 1624–1625, 1986. View at Google Scholar · View at Scopus
  16. A. L. Vahrmeijer, C. J. H. van de Velde, H. H. Hartgrink, and R. A. E. M. Tollenaar, “Treatment of melanoma metastases confined to the liver and future perspectives,” Digestive Surgery, vol. 25, no. 6, pp. 467–472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Pardo, Á. García, B. Thomas et al., “Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS,” Proteomics, vol. 5, no. 18, pp. 4980–4993, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. N. J. Borthwick, J. Thombs, M. Polak et al., “The biology of micrometastases from uveal melanoma,” Journal of Clinical Pathology, vol. 64, no. 8, pp. 666–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Wilkins, J.-C. Sanchez, A. A. Gooley et al., “Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it,” Biotechnology and Genetic Engineering Reviews, vol. 13, pp. 41–50, 1996. View at Google Scholar · View at Scopus
  20. J. P. A. Baak, E. A. M. Janssen, K. Soreide, and R. Heikkilæ, “Genomics and proteomics–the way forward,” Annals of Oncology, vol. 16, supplement 2, pp. ii30–ii44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Pardo, Á. García, R. Antrobus, M. J. Blanco, R. A. Dwek, and N. Zitzmann, “Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum,” Journal of Proteome Research, vol. 6, no. 7, pp. 2802–2811, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Knezevic, C. Leethanakul, V. E. Bichsel et al., “Proteomic profiling of the cancer microenvironment by antibody arrays,” Proteomics, vol. 1, no. 10, pp. 1271–1278, 2001. View at Google Scholar · View at Scopus
  24. M. F. Bande, M. Santiago, M. J. Blanco et al., “Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation,” Investigative Ophthalmology & Visual Science, vol. 53, no. 1, pp. 62–67, 2012. View at Google Scholar · View at Scopus
  25. D. E. Misek and E. H. Kim, “Protein biomarkers for the early detection of breast cancer,” International Journal of Proteomics, pp. 1–9, 2011. View at Google Scholar
  26. A. J. Cochran, G. N. Holland, D. R. Wen et al., “Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas,” Investigative Ophthalmology & Visual Science, vol. 24, no. 8, pp. 1153–1155, 1983. View at Google Scholar · View at Scopus
  27. A. J. Cochran, G. N. Holland, R. E. Saxton et al., “Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma,” British Journal of Ophthalmology, vol. 72, no. 11, pp. 874–879, 1988. View at Google Scholar · View at Scopus
  28. M.-C. Martins, J. J. Scull, C. E. Alcocer, J. Deschênes, E. Antecka, and M. N. Burnier Jr., “Immunohistochemical expression of S-100β in choroidal melanomas,” Canadian Journal of Ophthalmology, vol. 32, no. 6, pp. 378–381, 1997. View at Google Scholar · View at Scopus
  29. J. Kan-Mitchell, N. Rao, D. M. Albert, L. J. van Eldik, and C. R. Taylor, “S100 immunophenotypes of uveal melanomas,” Investigative Ophthalmology & Visual Science, vol. 31, no. 8, pp. 1492–1496, 1990. View at Google Scholar · View at Scopus
  30. G. S. O. A. Missotten, N. E. M. L. Tang, C. M. Korse et al., “Prognostic value of S-100-β serum concentration in patients with uveal melanoma,” Archives of Ophthalmology, vol. 121, no. 8, pp. 1117–1119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. G. P. M. Luyten, C. M. Mooy, J. Post, O. A. Jensen, T. M. Luider, and P. T. V. M. de Jong, “Metastatic in Uveal melanoma,” Cancer, vol. 78, no. 9, pp. 1967–1971, 1996. View at Publisher · View at Google Scholar
  32. M. Pardo, Á. García, B. Thomas et al., “The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker,” International Journal of Cancer, vol. 119, no. 5, pp. 1014–1022, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Chowers, R. Folberg, N. Livni, and J. Pe'er, “p53 immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid,” Current Eye Research, vol. 24, no. 2, pp. 105–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kishore, S. Ghazvini, D. H. Char, S. Kroll, and J. Selle, “p53 gene and cell cycling in uveal melanoma,” American Journal of Ophthalmology, vol. 121, no. 5, pp. 561–567, 1996. View at Google Scholar · View at Scopus
  35. K. Janßen, J. Kuntze, H. Busse, and K. W. Schmid, “P53 oncoprotein overexpression in choroidal melanoma,” Modern Pathology, vol. 9, no. 3, pp. 267–272, 1996. View at Google Scholar · View at Scopus
  36. M. Pardo, Á. García, R. Antrobus, M. J. Blanco, R. A. Dwek, and N. Zitzmann, “Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum,” Journal of Proteome Research, vol. 6, no. 7, pp. 2802–2811, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Zuidervaart, P. J. Hensbergen, M.-C. Wong et al., “Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression,” Investigative Ophthalmology & Visual Science, vol. 47, no. 3, pp. 786–793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Linge, S. Kennedy, D. O’Flynn et al., “Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did not,” Investigative Ophthalmology & Visual Science, vol. 53, no. 8, pp. 4634–4643, 2012. View at Google Scholar
  39. J. Beutel, J. Wegner, R. Wegner et al., “Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients,” Current Eye Research, vol. 34, pp. 1004–1009, 2009. View at Publisher · View at Google Scholar
  40. S. E. Coupland, H. Vorum, N. Mandal et al., “Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss,” Investigative Ophthalmology & Visual Science, vol. 51, no. 1, pp. 12–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Lüke, J. Wegner, R. Wegner et al., “Expression of c-Kit and its ligand SCF in primary uveal melanoma,” European Journal of Ophthalmology, vol. 21, no. 5, pp. 615–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. Singh, R. Tubbs, C. Biscotti, L. Schoenfield, and P. Trizzoi, “Chromosomal 3 and 8 status within hepatic metastasis of uveal melanoma,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 8, pp. 1223–1227, 2009. View at Google Scholar · View at Scopus
  43. J. Couturier and S. Saule, “Genetic determinants of uveal melanoma,” Developments in Ophthalmology, vol. 49, pp. 150–165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. K. Kuan, F. I. Jackson, and J. Hanson, “Multimodality detection of metastatic melanoma,” Journal of the Royal Society of Medicine, vol. 81, no. 10, pp. 579–582, 1988. View at Google Scholar · View at Scopus
  45. A. Klingenstein, I. Haritoglou, M. M. Schaumberger, M. M. Nentwich, R. Hein, and U. C. Schaller, “Receiver operating characteristic analysis: calculation for the marker ‘melanoma inhibitory activity’ in metastatic uveal melanoma patients,” Melanoma Research, vol. 21, no. 4, pp. 352–356, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Barak, J. Pe'er, I. Kalickman, and S. Frenkel, “VEGF as a biomarker for metastatic uveal melanoma in humans,” Current Eye Research, vol. 36, no. 4, pp. 386–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Jmor, H. Kalirai, A. taktak, B. Demato, and S. Coupland, “HSP-27 protein expression in uveal melanoma:correlation with predicting survival,” Acta Ophthalmologica, vol. 90, no. 6, pp. 543–539, 2012. View at Google Scholar
  48. I. W. Reiniger, U. C. Schaller, C. Haritoglou et al., ““Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 11, pp. 1161–1166, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Haritoglou, A. Wolf, T. Maier, C. Haritoglou, R. Hein, and U. C. Schaller, “Osteopontin and ‘melanoma inhibitory 1activity’: comparison of two serological tumor markers in metastatic uveal melanoma patients,” Ophthalmologica, vol. 223, no. 4, pp. 239–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. U. C. Schaller, A.-K. Bosserhoff, A. S. Neubauer, R. Buettner, A. Kampik, and A. J. Mueller, “Melanoma inhibitory activity: a novel serum marker for uveal melanoma,” Melanoma Research, vol. 12, no. 6, pp. 593–599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Ehlers and J. W. Harbour, “NBS1 expression as a prognostic marker in uveal melanoma,” Clinical Cancer Research, vol. 11, no. 5, pp. 1849–1853, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Mallikarjuna, V. Pushparaj, J. Biswas, and S. Krishnakumar, “Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study,” Current Eye Research, vol. 32, no. 3, pp. 281–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Sahin, H. Kiratli, F. Soylemezoglu, G. G. Tezel, S. Bilgic, and O. Saracbasi, “Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas,” Japanese Journal of Ophthalmology, vol. 51, no. 5, pp. 325–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. S.-H. Chang, L. A. Worley, M. D. Onken, and J. W. Harbour, “Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis,” Melanoma Research, vol. 18, no. 3, pp. 191–200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. C. C. Simões, M. K. Call, Z. M. Corrêa, A. G. Spaulding, and J. J. Augsburger, “Clinical and histopathological features and immunoreactivity of human choroidal and ciliary melanomas as prognostic factors for metastasis and death,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 12, pp. 1795–1803, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. G. S. O. A. Missotten, N. E. M. L. Tang, C. M. Korse et al., “Prognostic value of S-100-β serum concentration in patients with uveal melanoma,” Archives of Ophthalmology, vol. 121, no. 8, pp. 1117–1119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. G. S. Missotten, C. M. Korse, C. van Dehn et al., “S-100β protein and melanoma inhibitory activity protein in uveal melanoma screening: a comparison with liver function tests,” Tumor Biology, vol. 28, no. 2, pp. 63–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. U. C. Schaller, A.-K. Bosserhoff, A. S. Neubauer, R. Buettner, A. Kampik, and A. J. Mueller, “Melanoma inhibitory activity: a novel serum marker for uveal melanoma,” Melanoma Research, vol. 12, no. 6, pp. 593–599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. S. S. Kadkol, A. Y. Lin, V. Barak et al., “Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study,” Investigative Ophthalmology & Visual Science, vol. 47, no. 3, pp. 802–806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. V. Barak, S. Frenkel, I. Kalickman, A. J. Maniotis, R. Folberg, and J. Pe'er, “Serum markers to detect metastatic uveal melanoma,” Anticancer Research, vol. 27, no. 4 A, pp. 1897–1900, 2007. View at Google Scholar · View at Scopus
  61. V. Barak, S. Frenkel, K. Valyi-Nagy et al., “Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker,” Investigative Ophthalmology & Visual Science, vol. 48, no. 10, pp. 4399–4402, 2007. View at Publisher · View at Google Scholar · View at Scopus